Aethlon Medical (AEMD) vs Cerenome (CNSY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cerenome is the larger company by market cap ($13.6 million vs $9.7 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEMD | CNSY |
|---|---|---|
| Share price | $6.03 | $1.80 |
| Market cap | $9.67M | $13.62M |
| 1-day change | +0.33% | +0.28% |
| YTD return | — | -85.96% |
| 1-year return | — | -90.45% |
| 5-year return | — | -99.73% |
| EPS (TTM) | $-32.97 | $-3.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.00 | $19.00 |
| 52-week low | $1.41 | $1.49 |
| Distance from 52-week high | -83.70% | -90.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +119.73% | +1445.96% |
| Average volume | 2.56M | 121.12K |
| Shares outstanding | 1.60M | 7.59M |
| Employees | 9 | 28 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aethlon Medical
AEMD stock →Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states.
Health Care · Medical/Dental Instruments · 9 employees
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
AEMD vs CNSY FAQ
Which is bigger, Aethlon Medical or Cerenome?
Cerenome (CNSY) is larger, with a market capitalization of $13.62M compared with $9.67M for Aethlon Medical (AEMD).
Are Aethlon Medical and Cerenome in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.